RGNX
Regenxbio Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$7.20Close
$366.4MMarket cap
$5.65 – $15.9852-week range
Nov 5, 2026Next report · before the open
Highlights
Cautions
- Not in an uptrend 0 of 8 trend conditions
- Lagging the market RS 8 · weaker than 92% of stocks over 12 months
- Far from its high 55% below its 52-week high
- Results soon Nov 5, 2026, in 4 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
55%
1wk
up 7.8%
price change
1mo
down 4.4%
price change
12-month return
down 44%
market up 11% ·
its own down 55%
F-score
—
— Not assessed
Altman Z
-3.22
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
3.6×
price / book
Earnings yield
down 48.6%
EBIT / enterprise value
Cheaper than
17%
of the market · expensive
Revenue growth
up 105%
year on year
EPS growth
—
latest quarter
Sales growth
up 406%
latest quarter · +499 pts
ROE
down 107%
return on equity
Free cash margin
down 74%
-$126.4M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- Revenue reaccelerating (-8% then +105%)
Trade setup
ATR%
6.8%
$0.49 a day · 2×ATR $6.22
RS
8 / 99
vs the universe
Trend
0 / 8
trend template
Relative volume
0.7×
vs 50-day average
Up/down volume
0.72
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 0 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 2.7% over the year, from 50m to 51m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Last shock
Aug 24, 2026-25% in one session2.5× volumeon an SEC filing-11% since
Financials
- Gross
- Net -114%
- Free cash -74%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $154.6M | $470.3M | $112.7M | $90.2M | $83.3M | $170.4M |
| Gross margin | 77% | 89% | 52% | 59% | 60% | — |
| Operating income | -$119.2M | $160.0M | -$262.9M | -$268.1M | -$233.3M | -$161.2M |
| Net income | -$111.2M | $127.8M | -$280.3M | -$263.5M | -$227.1M | -$193.9M |
| Net margin | -72% | 27% | -249% | -292% | -273% | -114% |
| Earnings per share | -$2.98 | $2.91 | -$6.50 | -$6.02 | -$4.59 | -$3.76 |
| Free cash flow | -$80.9M | $134.7M | -$238.2M | -$228.4M | -$175.6M | -$126.4M |
| Free cash margin | -52% | 29% | -211% | -253% | -211% | -74% |
| Cash | $338.4M | $345.2M | $97.0M | $34.5M | $57.5M | $34.5M |
| Shareholders' equity | $377.8M | $764.3M | $516.2M | $311.7M | $259.7M | $102.7M |
| Shares outstanding | 37.48m | 42.83m | 43.30m | 44.05m | 49.55m | 50.89m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 14, 2026 | Quarterly ↗ | Mar 31, 2026 | 44d |
| Mar 5, 2026 | Annual ↗ | Dec 31, 2025 | 64d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 12, 2025 | Quarterly ↗ | Mar 31, 2025 | 42d |
| Mar 13, 2025 | Annual ↗ | Dec 31, 2024 | 72d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Aug 1, 2024 | Quarterly ↗ | Jun 30, 2024 | 32d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Feb 27, 2024 | Annual ↗ | Dec 31, 2023 | 58d |
| Nov 8, 2023 | Quarterly ↗ | Sep 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 16, 2026 | Director or officer change ↗ |
| Sep 23, 2026 | Material agreement ↗ |
| Aug 25, 2026 | Director or officer change ↗ |
| Aug 24, 2026 | Regulation FD · Other events ↗ |
| Aug 6, 2026 | Results ↗ |
| Jul 20, 2026 | Other events ↗ |
| Jun 29, 2026 | Other events ↗ |
| Jun 3, 2026 | Shareholder vote · Other events ↗ |
| May 14, 2026 | Results · Regulation FD · Other events ↗ |
| Mar 20, 2026 | Material agreement ↗ |
| Mar 5, 2026 | Results ↗ |
| Feb 10, 2026 | Regulation FD · Other events ↗ |